vardenafil

Vardenafil (Vivanza) is an oral therapy for the treatment of erectile dysfunction. It is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. During sexual stimulation, nitric oxide is released from nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide activates the enzyme guanylate cyclase resulting in increased synthesis of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum. The cGMP in turn triggers smooth muscle relaxation, allowing increased blood flow into the penis, resulting in erection. The tissue concentration of cGMP is regulated by both the rates of synthesis and degradation via phosphodiesterases (PDEs). The most abundant PDE in the human corpus cavernosum is the cGMPspecific phosphodiesterase type 5 (PDE5); therefore, the inhibition of PDE5 enhances erectile function by increasing the amount of cGMP.

Vardenafil hydrochloride trihydrate (BAY38-9456) is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively.

Vardenafil hydrochloride is a New Phosphodiesterase Type 5(PDE5) Inhibitor, in the Treatment of Erectile Dysfunction in Men With Diabetes

Vardenafil dihydrochloride (Levitra) is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively.

N-Desethyl vardenafil is a metabolite of vardenafil , a phosphodiesterase 5 inhibitor, that is formed by the action of cytochrome P450 (CYP)3A4 and CYP3A5.

Vardenafil oxopiperazine is an inhibitor of phosphodiesterase-5.

N-Desethyl-N-methyl Vardenafil, a potential impurity in commercial vardenafil preparations, functions as a phosphodiesterase 5 (PDE5) inhibitor, similar to its parent compound. With an IC50 value of 2 nM, it exhibits potent inhibitory activity against PDE5.

Vardenafil-d5 is a deuterated compound of Vardenafil. Vardenafil has a CAS number of 224785-90-4. Vardenafil (Levitra) is an oral therapy for the treatment of erectile dysfunction. It is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. During sexual stimulation, nitric oxide is released from nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide activates the enzyme guanylate cyclase resulting in increased synthesis of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum. The cGMP in turn triggers smooth muscle relaxation, allowing increased blood flow into the penis, resulting in erection. The tissue concentration of cGMP is regulated by both the rates of synthesis and degradation via phosphodiesterases (PDEs). The most abundant PDE in the human corpus cavernosum is the cGMPspecific phosphodiesterase type 5 (PDE5); therefore, the inhibition of PDE5 enhances erectile function by increasing the amount of cGMP.

N-Desethyl Vardenafil (Standard) is the standard substance of N-Desethyl Vardenafil, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. N-Desethyl vardenafil is a metabolite of vardenafil , a phosphodiesterase 5 inhibitor, that is formed by the action of cytochrome P450 (CYP)3A4 and CYP3A5.

N-Desethyl-N-Methyl Vardenafil (Standard) is the standard substance of N-Desethyl-N-Methyl Vardenafil, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. N-Desethyl-N-methyl Vardenafil, a potential impurity in commercial vardenafil preparations, functions as a phosphodiesterase 5 (PDE5) inhibitor, similar to its parent compound. With an IC50 value of 2 nM, it exhibits potent inhibitory activity against PDE5.

Vardenafil (Standard) is the standard substance of Vardenafil, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Vardenafil (Vivanza) is an oral therapy for the treatment of erectile dysfunction. It is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. During sexual stimulation, nitric oxide is released from nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide activates the enzyme guanylate cyclase resulting in increased synthesis of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum. The cGMP in turn triggers smooth muscle relaxation, allowing increased blood flow into the penis, resulting in erection. The tissue concentration of cGMP is regulated by both the rates of synthesis and degradation via phosphodiesterases (PDEs). The most abundant PDE in the human corpus cavernosum is the cGMPspecific phosphodiesterase type 5 (PDE5); therefore, the inhibition of PDE5 enhances erectile function by increasing the amount of cGMP.

Vardenafil hydrochloride (Standard) is the standard substance of Vardenafil hydrochloride, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Vardenafil hydrochloride is a New Phosphodiesterase Type 5(PDE5) Inhibitor, in the Treatment of Erectile Dysfunction in Men With Diabetes

Vardenafil Oxopiperazine (Standard) is the standard substance of Vardenafil Oxopiperazine, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Vardenafil oxopiperazine is an inhibitor of phosphodiesterase-5.

Acetylvardenafil is a novel analogue of Vardenafil where the sulfonyl group is replaced by an acetyl group. As a PDE-5 inhibitor, Acetylvardenafil is utilized in the research of erectile dysfunction (ED).

Thiovardenafil is the thiol analogue of the PDE 5 inhibitor Vardenafil.